ライフサイエンスコーパス: HTLV-II

1 HTLV-II coinfection was not associated with progression

2 HTLV-II infection significantly increased HCV load in wh

3 HTLV-II infection was found in all 20 Gran Chaco communi

4 HTLV-II infection was independently associated with an a

5 HTLV-II seroprevalence was highest at the two West Coast

6 HTLV-II VLs were higher in those subjects with subtype A

7 HTLV-II was significantly associated with a history of p

8 ransmissions/100 py [95% CI, 0.1-3.3]) and 2 HTLV-II transmissions/411 py (IR, 0.5 transmissions/100

9 of 6 visits in a subset of 30 HTLV-I- and 30 HTLV-II-infected subjects.

10 merase chain reaction in 122 HTLV-I- and 319 HTLV-II-infected subjects and serial VLs over the course

11 ge cohort of 127 HTLV-I-seropositive and 328 HTLV-II-seropositive former blood donors, by use of real

12 ion were studied in 154 HTLV-I-infected, 387 HTLV-II-infected, and 799 uninfected blood donors.

13 We followed 151 HTLV-I-seropositive, 387 HTLV-II-seropositive, and 799 HTLV-seronegative former b

14 rofile and titer of serum antibodies against HTLV-II antigens, as determined by Western immunoblots,

15 an extension of an earlier description of an HTLV-II-infected patient with neurologic disease and pre

16 dney infections for both HTLV-I (P=.005) and HTLV-II (P=.022).

17 mononuclear cells [PBMCs]/year; P=.042) and HTLV-II VLs did not change (slope, -0.019 log(10) copies

18 both HTLV-I (OR, 6.6; 99% CI, 2.2-19.2) and HTLV-II (OR, 2.8; 99% CI, 1.1-7.1) infection, although n

19 e HCV RNA, stratified by sex, race, HIV, and HTLV-II strata.

20 HTLV-I and HTLV-II associations with higher platelet counts suggest

21 Participants with HTLV-I and HTLV-II had higher adjusted platelet counts (+16 544 and

22 on assay, the Tax protein of both HTLV-I and HTLV-II specifically activated transcription from the IL

23 HTLV-I and HTLV-II viral transactivators, Tax1 and Tax2, are known

24 We measured HTLV-I and HTLV-II VLs in a large cohort of 127 HTLV-I-seropositive

25 echanism of long-term survival of HTLV-I and HTLV-II was studied in infected T cells in vitro and in

26 (eg, human T-lymphotropic virus [HTLV]-I and HTLV-II) and bacteria (eg, Staphylococcus aureus).

27 photropic viruses types I and II (HTLV-I and HTLV-II) cause chronic infections of T lymphocytes that

28 Results indicate that HTLV-I- and HTLV-II-infected T cells in vitro express high levels of

29 line increased the titer of both HTLV-I- and HTLV-II-pseudotyped viruses.

30 bsets of three individuals with asymptomatic HTLV-II infection or in our previous studies of a large

31 terminal repeat sequences from 15 Gran Chaco HTLV-II strains indicated that they constitute a highly

32 Culturing HTLV-II-infected PBMC that spontaneously proliferate (SL

33 oculated with either wild-type or pX-deleted HTLV-II developed a similar profile and titer of serum a

34 ta UT(6661-6984) cells containing UT-deleted HTLV-II; in most tissues, there was a fivefold to sevenf

35 In females, HTLV-II seropositivity was associated with early sexual

36 LV-I and positively with smoking (P=.08) for HTLV-II.

37 , and mesenteric lymph node were assayed for HTLV-II tax/rex sequences by quantitative polymerase cha

38 with control 729 cells remained negative for HTLV-II infection, as determined by the same techniques.

39 prospective incidence data, particularly for HTLV-II, are limited.

40 e, 0.05-5.95 log(10) copies/10(6) PBMCs) for HTLV-II (P<.0001).

41 ns from southern Argentina were positive for HTLV-II.

42 Furthermore, HTLV-II is spreading rapidly through new host population

43 The globular HTLV-II matrix structure is composed of four alpha-helic

44 +)/HTLV-II(-), HIV(-)/HTLV-II(+), and HIV(+)/HTLV-II(+) subjects, respectively.

45 up (HIV positive [HIV(+)]/HTLV-II(+), HIV(+)/HTLV-II negative [HTLV-II(-)], HIV(-)/HTLV-II(+), and HI

46 .50, 0.22, and 0.56 log(10) higher in HIV(+)/HTLV-II(-), HIV(-)/HTLV-II(+), and HIV(+)/HTLV-II(+) sub

47 and HIV/HTLV-II group (HIV positive [HIV(+)]/HTLV-II(+), HIV(+)/HTLV-II negative [HTLV-II(-)], HIV(-)

48 [HTLV-II(-)], HIV(-)/HTLV-II(+), and HIV(-)/HTLV-II(-)), 376 had HCV antibodies, of whom 305 had det

49 log(10) higher in HIV(+)/HTLV-II(-), HIV(-)/HTLV-II(+), and HIV(+)/HTLV-II(+) subjects, respectively

50 HIV(+)/HTLV-II negative [HTLV-II(-)], HIV(-)/HTLV-II(+), and HIV(-)/HTLV-II(-)), 376 had HCV antibodi

51 Compared with HIV(-)/HTLV-II(-) subjects, virus load was 0.50, 0.22, and 0.56

52 ta by sex, race (black or nonblack), and HIV/HTLV-II group (HIV positive [HIV(+)]/HTLV-II(+), HIV(+)/

53 antibodies among persons with or without HIV/HTLV-II coinfection in a cohort of 6,570 injection drug

54 d tax gene sequences were detected; however, HTLV-II proviral integration was not detected by Souther

55 ion with human T lymphotropic virus type II (HTLV-II) has been linked to an increased incidence of ba

56 for human T cell lymphotropic virus type II (HTLV-II) infection, a case-control study was conducted a

57 ) and/or human T-lymphotropic virus type II (HTLV-II) is common among drug users.

58 Human T-cell lymphotropic virus type II (HTLV-II) is endemic in several ethnic tribes and among i

59 in from human T-cell leukemia virus type II (HTLV-II), a member of the human oncovirus subclass of re

60 HIV and human T-lymphotropic virus type II (HTLV-II), are at high risk for end-stage liver disease (

61 a primary etiologic agent in CTCL; and (ii) HTLV-II pol and tax gene sequences can be detected in a

62 than in HTLV-II infection and was higher in HTLV-II subtype A than in HTLV-II subtype B infection.

63 sed prevalence of a variety of infections in HTLV-II-positive donors suggests immunologic impairment.

64 L was significantly higher in HTLV-I than in HTLV-II infection and was higher in HTLV-II subtype A th

65 and was higher in HTLV-II subtype A than in HTLV-II subtype B infection.

66 ta support a role for sexual transmission in HTLV-II infection.

67 pt of a blood transfusion (P=.04), and lower HTLV-II VL was associated with female sex (P=.007).

68 HIV(+)]/HTLV-II(+), HIV(+)/HTLV-II negative [HTLV-II(-)], HIV(-)/HTLV-II(+), and HIV(-)/HTLV-II(-)),

69 hese various populations, the association of HTLV-II with disease is sparse and mainly limited to iso

70 l immune responses, we immunized a cohort of HTLV-II-infected subjects and matched uninfected control

71 re consistent with a 30-year-old epidemic of HTLV-II in the United States due to injection drug use a

72 that UT sequences in the proximal portion of HTLV-II are not necessary for infection but confer incre

73 Despite the presence of HTLV-II in these various populations, the association of

74 The prevalence of HTLV-II increased with age (14% in those < 13 years and

75 ion, as well as spontaneous proliferation of HTLV-II-infected PBMC.

76 ax2 may result in a shorter survival time of HTLV-II-infected cells in vivo and a diminished risk of

77 The incidence of sexual transmission of HTLV-II may be similar to that of HTLV-I, and female-to-

78 Virus load increment with HIV or HTLV-II infection was higher among white subjects than a

79 In tissues from one patient, HTLV-II pol and tax gene sequences were detected; howeve

80 The presence of proviral HTLV-II was confirmed by polymerase chain reaction analy

81 ly disparate host populations, the resultant HTLV-II/STLV-II phylogeny exhibits little phylogeographi

82 creasing age-specific HTLV-I seroprevalence, HTLV-II prevalence rose until age 40-49 years and declin

83 These results suggest that HTLV-II does not affect the progression of HIV infection

84 The HTLV-II effect on lymphocytes is novel and may be relate

85 Clear structural similarities between the HTLV-II and HIV-1 matrix proteins suggest that the topol

86 clinical and immunologic findings from these HTLV-II-infected patient resemble those found in HTLV-I-

87 Thus, HTLV-II-infected persons develop robust humoral response

88 ed specimens were positive for antibodies to HTLV-II.

89 inal fluid and serum contained antibodies to HTLV-II.

90 nsfected with either a full-length wild-type HTLV-II clone (pH6neo) or a mutant clone containing a 32

91 ed with 729pH6neo cells containing wild-type HTLV-II, which contained between 1.4 and 0.3 mean copies

92 pared with rabbits inoculated with wild-type HTLV-II.

93 The mechanism(s) underlying HTLV-II-associated SLP in vitro involve increased utiliz

94 Human T cell leukemia/lymphoma virus (HTLV-II) type II infection was detected by polymerase ch

95 Of 370 IDUs, 61 (16%) were HTLV-II-coinfected.

96 TLV-I seropositive and 384 (22.3/10(5)) were HTLV-II seropositive.

97 T-cell lymphocytic leukemia (ATLL), whereas HTLV-II has not been associated with hematopoietic malig

98 To determine whether HTLV-II infection is associated with impaired humoral im

99 azards models were used to determine whether HTLV-II infection was associated with AIDS or AIDS-relat

100 85 HTLV-positive (30 with HTLV-I and 55 with HTLV-II) blood donors and their stable (>or=6 months) he

101 rcourse with prostitutes was associated with HTLV-II seropositivity (OR, 1.68; CI, 1.04-2.72).

102 n of lymphocytes from patients infected with HTLV-II and expression of CD80, which could be blocked b

103 Participants with HTLV-II had significant (P < .05) increases in their adj

104 and immunologic findings of 4 patients with HTLV-II seropositivity and spastic paraparesis.